Sign In
Buy BMRN
$56.47
+1.81 (+3.31%)
At Close: Jun 04, 2026
What This FDA Response Means for BioMarin’s Gene Therapy for Hemophilia
09:55am, Wednesday, 19'th Aug 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) stock was crushed on Wednesday after the company announced that the U.S.
BioMarin's stock falls 27% after FDA asks for additional data about experimental hemophilia A drug
09:42am, Wednesday, 19'th Aug 2020
Shares of BioMarin Pharmaceutical Inc. BMRN, -30.76% tumbled 27.6% in trading on Wednesday after the company said it had received a complete response letter from the Food and Drug Administration for i
BioMarin Handed Setback By FDA On Hemophilia Drug; BMRN Stock Plunges
09:38am, Wednesday, 19'th Aug 2020
BioMarin Pharmaceutical on Wednesday said the U.S. Food and Drug Administration wants more data on its hemophilia A gene therapy.
BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
08:00am, Wednesday, 19'th Aug 2020
FDA Introduces New Recommendation for 2-Year Annualized Bleeding Rate (ABR) as Primary Endpoint for Ongoing Phase 3 Study 270-301
BioMarin Shares Slammed After Hemophilia A Gene Therapy Stumbles At FDA
12:00am, Wednesday, 19'th Aug 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) shares were plunging Wednesday after a negative outcome for a binary event.
BioMarin Investors Disappointed By FDA News: The FDA...
Why I'm Worrying Over A Market Drop
04:22pm, Monday, 17'th Aug 2020
Our overbought indicator reaches rarefied air. It could be a good time to rein in risk by reducing margin and avoiding short-term calls.
Stocks To Watch: Walmart, Target, Kandi And Gold vs. Bitcoin
08:30am, Saturday, 15'th Aug 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
BioMarin's MAA for Dwarfism Candidate Gets EMA Validation
03:57pm, Friday, 14'th Aug 2020
The EMA sanctions BioMarin's (BMRN) marketing authorization application for vosoritide to treat children with achondroplasia, the most common type of dwarfism.
BioMarin's MAA for Dwarfism Candidate Gets EMA Validation
11:57am, Friday, 14'th Aug 2020
The EMA sanctions BioMarin's (BMRN) marketing authorization application for vosoritide to treat children with achondroplasia, the most common type of dwarfism.
Ascendis' Dwarfism Candidate Gets Orphan Drug Status in EU
04:48pm, Thursday, 13'th Aug 2020
Ascendis' (ASND) TransCon CNP receives an Orphan Drug tag in Europe for the treatment of achondroplasia, the most common type of dwarfism.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) validated the Company's Marketing Authorization Application (MAA) for vosoritide, an investigationa
Cambridge Investment Research Advisors Inc. Buys Shares of 4,231 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
11:56am, Tuesday, 11'th Aug 2020
Cambridge Investment Research Advisors Inc. purchased a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the second quarter, according to its most recent disclosure with the SEC. The inst
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
12:30pm, Monday, 10'th Aug 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jeff Ajer, Executive Vice President and Chief Commercial Officer, and Brian Mueller, Executive Vice President, Chief Financial Officer
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
08:30am, Monday, 10'th Aug 2020
SAN RAFAEL, Calif., Aug. 10, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc.
5 Midcap Magic Formula Stocks For Total Return
10:34pm, Friday, 07'th Aug 2020
Considering all that has happened in 2020, I thought it might be interesting to present a screen of stocks based on Joel Greenblatt’s magic formula.
